Added to YB: 2024-06-26
Pitch date: 2024-06-20
EIGRQ [bullish]
Eiger BioPharmaceuticals, Inc.
-5.94%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases.
Market Cap
$17.1M
Pitch Price
$10.10
Price Target
18.44 (+94%)
Dividend
N/A
Sector
Biotechnology
Category
special_situation
Eiger BioPharmaceuticals: Potential Upside in Restructuring and Asset Monetization
EIGRQ: $30.11/sh cash + Lonafarnib value. $80.8M from Zokinvy/Avexitide sale. Low burn rate in Ch11. Propel Bio sees value in Lonafarnib for HDV. $18.44 PT, 45% upside. Max position 67.5K shares (4.5% of float). $9M paid to Merck from Zokinvy. Potential +$8/sh if burn excludes creditor claims.
Read full article (1 min)